CRIS Q3 2025 Earnings Call Summary

Net Loss: $7.7 million, or $0.49 per share, for Q3 2025, an improvement from a net loss of $10.1 million, or $1.70 per share, in Q3 2024.
Year-to-Date Loss: $26.9 million, or $2.19 per share, for the first nine months of 2025, compared to a loss of $33.8 million, or $5.77 per share, in the same period of 2024.
R&D Expenses: $6.4 million for Q3 2025, down from $9.7 million in Q3 2024; $22.4 million for the first nine months of 2025, down from $29.6 million in 2024.
G&A Expenses: $3.7 million for Q3 2025, slightly down from $3.8 million in Q3 2024; $11.2 million for the first nine months of 2025, down from $13.4 million in 2024.
Cash Position: $9.1 million as of September 30, 2025, expected to fund operations into 2026.

TakeAim Lymphoma Study: Progressing with emavusertib in combination with ibrutinib for primary CNS lymphoma, with plans for accelerated submissions to the FDA and EMA.
CLL Program: Initiating a proof-of-concept study to evaluate emavusertib in patients on BTKi monotherapy who have not achieved complete remission. Initial patient enrollment expected in late Q4 2025 or early Q1 2026.
AML Triplet Study: Initial results from a study combining emavusertib with azacitidine and venetoclax show promising MRD conversion rates, with further exploration of dosing regimens planned.

Curis aims to enroll additional patients for the TakeAim Lymphoma study over the next 12 to 18 months to support regulatory submissions.
Initial data from the CLL study is anticipated to be presented at the ASH Annual Meeting in December 2026.
The company is actively seeking additional capital to support ongoing and new clinical trials.

Despite improved financial metrics, the company continues to operate at a loss, which raises concerns about long-term sustainability without additional funding.
The need for further capital raises questions about resource allocation, particularly between the CLL and AML studies.
Potential risks associated with the CLL study include the safety profile of the emavusertib and BTK inhibitor combination, although initial data suggests no significant additive toxicities.

FDA Discussions: The company is aligned with the FDA regarding the CLL study's primary endpoints and study design, with a focus on addressing unmet needs in the CLL community.
Study Size and Expectations: The CLL trial is expected to involve around 40 patients, with hopes of achieving a complete remission rate above 20%.
Resource Prioritization: Curis is prioritizing the ongoing PCNSL trial and the new CLL trial while planning for capital acquisition before year-end.
SNO Conference Expectations: Curis plans to present multiple posters at the upcoming SNO conference, focusing on the progress in PCNSL and secondary CNS lymphoma.

Overall, Curis is making significant strides in its clinical programs while managing financial losses and preparing for future capital needs.

CRIS — Curis, Inc.